sumatriptan has been researched along with fluoxetine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (29.17) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Szabo, CP | 1 |
| Bonanno, G; Fassio, A; Raiteri, M; Ruelle, A; Severi, P | 1 |
| Joffe, RT; Sokolov, ST | 1 |
| Pomp, E | 1 |
| Schwartz, CE | 1 |
| Chariot, J; Nagain-Domaine, C; Presset, O; Rozé, C | 1 |
| Ackland, MJ; Alex, AA; de Groot, MJ; Horne, VA; Jones, BC | 1 |
| Finfgeld, DL | 1 |
| Bhat, MG; Foley, CE; Gilbertson, TA; Jordt, RM; Khan, MA | 1 |
| Ali, AS; Ali, SA; Salim, S | 1 |
| Kilinc, E; Kılınc, YB; Torun, IE | 1 |
2 review(s) available for sumatriptan and fluoxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Serotonin syndrome and the use of SSRIs.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypericum; Incidence; Medical History Taking; Migraine Disorders; Nurse's Role; Nursing Assessment; Phototherapy; Primary Prevention; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Serotonin Syndrome; Sumatriptan | 2004 |
22 other study(ies) available for sumatriptan and fluoxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Fluoxetine and sumatriptan: possibly a counterproductive combination.
Topics: Acute Disease; Adult; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Migraine Disorders; Sumatriptan | 1995 |
Fenfluramine releases serotonin from human brain nerve endings by a dual mechanism.
Topics: Calcium; Cerebral Cortex; Fenfluramine; Fluoxetine; Humans; Nerve Endings; Serotonin; Sumatriptan; Synaptosomes; Tritium | 1994 |
Co-administration of fluoxetine and sumatriptan: the Canadian experience.
Topics: Canada; Depression; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Migraine Disorders; Product Surveillance, Postmarketing; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sumatriptan | 1997 |
[Interaction between sumatriptan and selective serotonin uptake inhibitors].
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Sumatriptan; Vasoconstrictor Agents | 1998 |
A surfeit of serotonin: sumatriptan and serotonergic antidepressants.
Topics: Antidepressive Agents, Second-Generation; Colitis; Depressive Disorder; Drug Synergism; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 1999 |
Effect of sumatriptan on external pancreatic secretion and its interaction with endogenous norepinephrine in the rat.
Topics: Acetylcholine; Animals; Deoxyglucose; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electric Stimulation; Fluoxetine; Male; Norepinephrine; Pancreas; Pancreatic Fistula; Rats; Rats, Wistar; Serotonin Receptor Agonists; Sumatriptan; Vagus Nerve | 1999 |
A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Betaxolol; Cytochrome P-450 CYP2D6; Dealkylation; Fluoxetine; Loratadine; Models, Molecular; Pharmaceutical Preparations; Procainamide; Ritonavir; Substrate Specificity; Sumatriptan | 1999 |
Validation of a rat behavioral avoidance model from a drug delivery perspective.
Topics: Animals; Avoidance Learning; Behavior, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ergotamine; Fluoxetine; Inhibitory Concentration 50; Male; Models, Animal; Rats; Reproducibility of Results; Sumatriptan; Taste Threshold; Water Deprivation | 2005 |
5-HT receptor subtypes as key targets in mediating pigment dispersion within melanophores of teleost, Oreochromis mossambicus.
Topics: Allylbenzene Derivatives; Animals; Benzyl Compounds; Dioxolanes; Dose-Response Relationship, Drug; Fish Proteins; Fluoxetine; Melanins; Melanophores; Metergoline; Pigments, Biological; Pyrogallol; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Sumatriptan; Tilapia; Trazodone; Yohimbine | 2013 |
Endogenous and exogenous serotonin, but not sumatriptan, ameliorate seizures and neuroinflammation in the pentylenetetrazole-induced seizure model in rats.
Topics: Animals; Anticonvulsants; Epilepsy; Fluoxetine; Humans; Interleukin-6; Male; Neuroinflammatory Diseases; Pentylenetetrazole; Rats; Rats, Wistar; Seizures; Serotonin; Sumatriptan; Tumor Necrosis Factor-alpha | 2022 |